|
|
Post by falconquest on Jan 5, 2016 22:35:34 GMT -5
Can anyone tell me how Mannkind marketing efforts are impacted after today? In other words, if Mannkind markets Afrezza successfully in another country (for example) do they still share 65%/35% with Sanofi until July 4th or do they get to control it now? Same with pricing.....does Mannkind get control now or do they have to wait until July. I'm concerned about the next 6 months here, what if they sign an agreement with another BP, do they have to wait until Sanofi is out of the picture in July to move forward? If this was discussed and I missed it then I apologize. Thanks!
|
|
|
|
Post by mnkdmorelong on Jan 5, 2016 22:50:35 GMT -5
As of yesterday, SNY no longer has exclusive rights to market Afrezza. MNKD could fill purchase orders now.
Whatever SNY sells its 65/35. If MNKD, its 100%.
The reality is that MNKD does not have the organization to market Afrezza. There will be chaos until a new sales/marketing structure is put in place.
I can see MNKD getting aggressive and appointing a company like CVS or Walgreens Boots to be the exclusive vendor for Afrezza. This gets the locations and insurance payment system. In other words, script fulfillment is done. Now they have to figure out how to sell to docs and patients. It will not be easy.
When MNKD does come up with their plan, they still need money to make it work.
|
|
|
|
Post by jdvinvestments on Jan 5, 2016 23:22:37 GMT -5
Pursuant to the Web conference today: MMNKD is going to be just fine as Sanofi will market and sell until July 4 and MNKD can also begin selling alongside Sanofi until July 4th when they will retain all sales and marketing rights. These rights get more valuable each day as there are more customers each day. With 60 million in cash and uncle Al Mann who has provided another $30 million if needed as a loan the company will do just fine and hopefully will be profitable by year end. This will propel the stock skyward so now is the best time the lowest price to buy this great stock. I love to recommend stocks that are on sale now with unlimited up side. What say you all... is tomorrow a good time to buy or are you going to let me make all the profits?
|
|
|
|
Post by dreamboatcruise on Jan 6, 2016 1:48:04 GMT -5
Pursuant to the Web conference today: MMNKD is going to be just fine as Sanofi will market and sell until July 4 and MNKD can also begin selling alongside Sanofi until July 4th when they will retain all sales and marketing rights. These rights get more valuable each day as there are more customers each day. With 60 million in cash and uncle Al Mann who has provided another $30 million if needed as a loan the company will do just fine and hopefully will be profitable by year end. This will propel the stock skyward so now is the best time the lowest price to buy this great stock. I love to recommend stocks that are on sale now with unlimited up side. What say you all... is tomorrow a good time to buy or are you going to let me make all the profits? Whew... well as long as they vaguely acted like everything will be fine... it's not as if they don't give a disclaimer at the start saying they are forward looking statements that may well not become reality. Profitably by the end of which year? |
|
|
|
Post by mnkdmorelong on Jan 6, 2016 4:58:47 GMT -5
Pursuant to the Web conference today: MMNKD is going to be just fine as Sanofi will market and sell until July 4 and MNKD can also begin selling alongside Sanofi until July 4th when they will retain all sales and marketing rights. These rights get more valuable each day as there are more customers each day. With 60 million in cash and uncle Al Mann who has provided another $30 million if needed as a loan the company will do just fine and hopefully will be profitable by year end. This will propel the stock skyward so now is the best time the lowest price to buy this great stock. I love to recommend stocks that are on sale now with unlimited up side. What say you all... is tomorrow a good time to buy or are you going to let me make all the profits? Everything is not all right with MNKD. Afrezza sales are only $10 mln/yr (growing). This business does not spin off enough cash to support itself (now) and pay MNKD's corporate bills. Financing will be needed. |
|
|
|
Post by benh on Jan 6, 2016 6:41:50 GMT -5
Pursuant to the Web conference today: MMNKD is going to be just fine as Sanofi will market and sell until July 4 and MNKD can also begin selling alongside Sanofi until July 4th when they will retain all sales and marketing rights. These rights get more valuable each day as there are more customers each day. With 60 million in cash and uncle Al Mann who has provided another $30 million if needed as a loan the company will do just fine and hopefully will be profitable by year end. This will propel the stock skyward so now is the best time the lowest price to buy this great stock. I love to recommend stocks that are on sale now with unlimited up side. What say you all... is tomorrow a good time to buy or are you going to let me make all the profits? Profitable by year end? That's not hope, that is delusional. Remove the 1st two months as launch. The growth is around 3%. Assuming organic growth continues at the same rate, that's a revenue total of 35m$ for 2016. Want more growth, faster growth, then their #1 priority is proving Afrezza is as good as what Al Mann and the advocates say it is. Instead, this happened: Quoting Matt Pfeffer: ....., a writer named David -- and I'll spare the rest of his name -- sent me a note Friday typical of many others I've received. In it he recounted a lot of anecdotal information regarding the widely reported successes people have had using Afrezza to dramatically lower their HbA1c numbers even while eating foods they could not before, yet avoiding complications and greatly improving their lives. He suggested we use such patient testimonials on calls such as this and in Afrezza advertising. He further suggested that we email every diabetic and doctor in the US and suggest they do their diligence to look into Afrezza with links to these testimonials. The problem with this suggestion is that it is not allowed by the FDA as advertisements and public reporting of patient results may only be as a result of a controlled FDA-approved study. Such anecdotal information is not allowed to be used by us to promote the product. I'm happy to suggest that everyone consider using Afrezza and to do their own diligence, including the information located on Afrezza.com and if you are amongst those using it and happy, please feel free to share your experience with your doctors and your friends. MannKind's efforts must stop there.
|
|
|
|
Post by mnholdem on Jan 6, 2016 8:44:08 GMT -5
13.3 Rights on Termination Other than Termination By Sanofi for Cause.
(a) Wind-down Period.
(ii) Commercialization. Sanofi and its Affiliates and sublicensees shall continue, to the extent that Sanofi and its Affiliates and sublicensees continue to have stocks of usable Product, to fulfill orders received from customers for Product in the Field in the Territory until up to 180 days after the later of (A) the date on which MannKind notifies Sanofi in writing that MannKind intends to Commercialize such Product or has secured an alternative distributor or licensee for the Product and (B) Sanofi has initiated transition of the MAAs and Marketing Approvals for Product in the Field in the Territory to MannKind or such distributor or licensee, but in no event for more for than 12 months after the date of notice of termination. For Product sold by Sanofi after the effective date of a termination (i.e., after the expiration of the applicable termination notice period), the profit-or-loss provisions in Section 6.3 shall continue to apply. Notwithstanding the foregoing, Sanofi and its Affiliates and sublicensees shall cease such activities in the Territory upon 60 days written notice given by MannKind at any time after the effective date of a termination requesting that such activities (or portion thereof) cease.
---
(f) Licenses. Sanofi hereby grants to MannKind, effective upon termination of this Agreement, a non-exclusive, worldwide (or in the event of a Partial Termination, in the applicable Terminated Region), royalty-free, fully-paid license (with rights to sublicense) to use all Sanofi Technology and any Information and Regulatory Filings generated by Sanofi or its Affiliates with respect to Product, then Controlled by Sanofi or any of its Affiliates as of the effective date of termination, to Develop, Manufacture, have Manufactured, use, Commercialize and have Commercialized Product in its form as of the effective date of termination (but excluding any improvements thereafter).
I'm wondering if this not only includes all printed materials for use in physician training and DTC mailings, but also the Afrezza.com and AffrezzaPro.com websites, which must be transferred to MannKind Corporation, albeit with any Sanofi affiliation removed. Even if MannKind only paid 35% of the expense, I believe that "Sanofi Technology and any Information and Regulatory Filings generated by Sanofi..." must be made available to MannKind Corporation without additional charge (i.e. "fully-paid license").
Is this a correct interpretation? |
|
|
|
Post by matt on Jan 6, 2016 9:21:44 GMT -5
I believe that "Sanofi Technology and any Information and Regulatory Filings generated by Sanofi..." must be made available to MannKind Corporation without additional charge (i.e. "fully-paid license").
Is this a correct interpretation? That is usually how it works when partnership agreements are unwound. The departing partner has no further interest in the drug, and they really don't care if their former partner uses the information to their benefit as the expense is water under the bridge. The value of such information is not that substantial since the documents must be rewritten to remove all references to Sanofi, but they do serve as an outline and probably save a bit of time. |
|
